P Vodvářka

728 total citations
16 papers, 534 citations indexed

About

P Vodvářka is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, P Vodvářka has authored 16 papers receiving a total of 534 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 6 papers in Pulmonary and Respiratory Medicine and 3 papers in Surgery. Recurrent topics in P Vodvářka's work include Cancer Treatment and Pharmacology (7 papers), Lung Cancer Treatments and Mutations (5 papers) and Multiple and Secondary Primary Cancers (2 papers). P Vodvářka is often cited by papers focused on Cancer Treatment and Pharmacology (7 papers), Lung Cancer Treatments and Mutations (5 papers) and Multiple and Secondary Primary Cancers (2 papers). P Vodvářka collaborates with scholars based in Czechia, United States and Germany. P Vodvářka's co-authors include Laura Hargreaves, Danny Rischin, Chonlakiet Khorprasert, Serban Ghiorghiu, Everett E. Vokes, Lisa Licitra, J.S.W. Stewart, Denis Soulières, Alison Armour and Ezra E.W. Cohen and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

P Vodvářka

15 papers receiving 521 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
P Vodvářka Czechia 9 368 232 178 118 94 16 534
Lisle Nabell United States 9 244 0.7× 89 0.4× 157 0.9× 152 1.3× 80 0.9× 25 481
Beatriz Cirauqui Spain 13 357 1.0× 197 0.8× 101 0.6× 108 0.9× 168 1.8× 56 549
Ansfield Fj United States 11 252 0.7× 143 0.6× 157 0.9× 71 0.6× 36 0.4× 28 457
Kelly K. Curtis United States 12 130 0.4× 146 0.6× 61 0.3× 107 0.9× 31 0.3× 25 375
Pradeep Thanigaimani United States 7 503 1.4× 175 0.8× 177 1.0× 71 0.6× 56 0.6× 11 669
Franco Vito Piantedosi Italy 12 519 1.4× 432 1.9× 16 0.1× 92 0.8× 124 1.3× 14 698
Irene Grimani Greece 8 167 0.5× 83 0.4× 30 0.2× 44 0.4× 65 0.7× 11 363
J. Schüller Austria 11 251 0.7× 69 0.3× 30 0.2× 58 0.5× 36 0.4× 30 351
Raúl Vera United States 10 218 0.6× 128 0.6× 25 0.1× 74 0.6× 44 0.5× 14 412
María Jesús Quintana Spain 10 205 0.6× 77 0.3× 131 0.7× 50 0.4× 113 1.2× 11 424

Countries citing papers authored by P Vodvářka

Since Specialization
Citations

This map shows the geographic impact of P Vodvářka's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by P Vodvářka with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites P Vodvářka more than expected).

Fields of papers citing papers by P Vodvářka

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by P Vodvářka. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by P Vodvářka. The network helps show where P Vodvářka may publish in the future.

Co-authorship network of co-authors of P Vodvářka

This figure shows the co-authorship network connecting the top 25 collaborators of P Vodvářka. A scholar is included among the top collaborators of P Vodvářka based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with P Vodvářka. P Vodvářka is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Stewart, J.S.W., Ezra E.W. Cohen, Lisa Licitra, et al.. (2009). Phase III Study of Gefitinib Compared With Intravenous Methotrexate for Recurrent Squamous Cell Carcinoma of the Head and Neck. Journal of Clinical Oncology. 27(11). 1864–1871. 267 indexed citations
2.
Stewart, J.S.W., Ezra E.W. Cohen, Lisa Licitra, et al.. (2007). A Phase III randomized parallel-group study of gefitinib (IRESSA) versus methotrexate (IMEX) in patients with recurrent squamous cell carcinoma of the head and neck. Cancer Research. 67. 3522–3522. 18 indexed citations
3.
Dittrich, Christian, Luboš Petruželka, P Vodvářka, et al.. (2006). A Phase I Study of Pemetrexed (ALIMTA) and Cyclophosphamide in Patients with Locally Advanced or Metastatic Breast Cancer. Clinical Cancer Research. 12(23). 7071–7078. 13 indexed citations
4.
Feher, Olavo, P Vodvářka, Jacek Jassem, et al.. (2005). First-line gemcitabine versus epirubicin in postmenopausal women aged 60 or older with metastatic breast cancer: a multicenter, randomized, phase III study. Annals of Oncology. 16(6). 899–908. 66 indexed citations
5.
Baselga, José, Antonio Llombart‐Cussac, Meritxell Bellet, et al.. (2003). Randomized, double-blind, multicenter trial comparing two doses of arzoxifene (LY353381) in hormone-sensitive advanced or metastatic breast cancer patients. Annals of Oncology. 14(9). 1383–1390. 30 indexed citations
6.
Martín, Miguel, M. Spielmann, M Namer, et al.. (2003). Phase II study of pemetrexed in breast cancer patients pretreated with anthracyclines. Annals of Oncology. 14(8). 1246–1252. 40 indexed citations
7.
8.
Mayer, Jiřı́, Ingrid Vášová, Zdeněk Kořı́stek, et al.. (2001). Ifosfamide- and etoposide-based chemotherapy as salvage and mobilizing regimens for poor prognosis lymphoma.. PubMed. 64. 21–7. 6 indexed citations
9.
Mayer, Jiřı́, Zdeněk Kořı́stek, Ingrid Vášová, Jiří Vorlíček, & P Vodvářka. (1999). Ifosfamide and etoposide-based chemotherapy as salvage and mobilizing regimens for poor prognosis lymphoma. Bone Marrow Transplantation. 23(5). 413–419. 13 indexed citations
10.
Sedláček, Zdeněk, Roman Kodet, E Seemanová, et al.. (1998). Two Li-Fraumeni syndrome families with novel germline p53 mutations: loss of the wild-type p53 allele in only 50% of tumours. British Journal of Cancer. 77(7). 1034–1039. 35 indexed citations
11.
Mayer, Jiřı́, Zdeněk Kořı́stek, Ingrid Vášová, et al.. (1998). [Chemotherapy of resistant and recurrent lymphoma based on a combination of ifosfamide and etoposide. Antitumor effects, toxicity and stimulation of peripheral stem cells].. PubMed. 137(19). 590–7. 1 indexed citations
12.
Petruželka, Luboš, J. Fischer, M Kůta, et al.. (1998). [Comparison of adjuvant chemotherapy in breast carcinoma with a combination of cyclophosphamide, methotrexate, 5-fluorouracil (CMF) and AC (doxorubicin, cyclophosphamide). Initial results of a national cooperative study].. PubMed. 99(1). 25–31. 1 indexed citations
13.
Vodvářka, P. (1989). [Treatment of the superior vena cava syndrome].. PubMed. 43(3). 185–93. 1 indexed citations
14.
Vodvářka, P, et al.. (1988). Bacterial infection of urine in patients with bladder cancer.. PubMed. 35(2). 243–50. 2 indexed citations
15.
Vodvářka, P, et al.. (1985). Ototoxicity of cis-diamminedichloroplatinum.. PubMed. 32(2). 229–38. 3 indexed citations
16.
Kolář, Zdeněk, et al.. (1983). Tissue-specific inhibition of embryonic neural cell proliferation by rat brain extract. Cellular and Molecular Life Sciences. 39(2). 168–169. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lisle Nabell Breakdown of academic impact, for papers by Beatriz Cirauqui Breakdown of academic impact, for papers by Ansfield Fj Breakdown of academic impact, for papers by Kelly K. Curtis Breakdown of academic impact, for papers by Pradeep Thanigaimani Breakdown of academic impact, for papers by Franco Vito Piantedosi Breakdown of academic impact, for papers by Irene Grimani Breakdown of academic impact, for papers by J. Schüller Breakdown of academic impact, for papers by Raúl Vera Breakdown of academic impact, for papers by María Jesús Quintana
Rankless by CCL
2026